CEREVEL THERAPEUTICS HOLDINGS, INC.
CIK 0001805387
Revenue (TTM)
$0
Q1 Apr 2024
Net Income (TTM)
−$432.09M
−23.1% YoY
Q1 Apr 2024
EPS Diluted (TTM)
−$2.64
−15.1% YoY
Q1 Apr 2024
Gross Margin
—
Q1 Apr 2024
Operating Margin
—
Q1 Apr 2024
Net Margin
—
Q1 Apr 2024
Free Cash Flow (TTM)
−$326.12M
Q1 Apr 2024
Cash
$320.44M
Q1 Apr 2024
Total Debt
$375.19M
Q1 Apr 2024
Shares Outstanding
182.19M sh
Q1 Apr 2024
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.